Beam Therapeutics Inc Revenue Growth Rates (BEAM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Beam Therapeutics Inc   (NASDAQ: BEAM)
 

BEAM's Revenue Growth by Quarter and Year

Beam Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BEAM/growth
https://api.csimarket.com/api/v1/companies/BEAM/fundamentals
https://api.csimarket.com/api/v1/companies/BEAM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BEAM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.31
2nd Quarter June 0.49
1st Quarter March 31.74
FY 32.54

BEAMs Annual Revenue
Beam Therapeutics Inc 's Revenue in the fiscal year 2025 $ 139.74 millions
Beam Therapeutics Inc 's Revenue in the fiscal year 2024 $ 63.52 millions
Beam Therapeutics Inc 's Revenue in the fiscal year 2023 $ 377.71 millions
Beam Therapeutics Inc 's Revenue in the fiscal year 2022 $ 60.92 millions
Beam Therapeutics Inc 's Revenue in the fiscal year 2021 $ 51.84 millions




BEAM Revenue third quarter 2026 Y/Y Growth Comment
Beam Therapeutics Inc reported drop in Revenue in the third quarter 2026 by -96.84% to $ 0.31 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Beam Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 25693.72%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 70 other companies have achieved higher Revenue growth. While Beam Therapeutics Inc ' s Revenue meltdown of -96.84% ranks overall at the positon no. 3918 in the third quarter 2026.


BEAM Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -96.84 %
2nd Quarter June -94.21 %
1st Quarter March 324.9 %
FY   -

Financial Statements
Beam Therapeutics Inc 's third quarter 2026 Revenue $ 0.31 millions BEAM's Income Statement
Beam Therapeutics Inc 's third quarter 2025 Revenue $ 9.70 millions Quarterly BEAM's Income Statement


BEAM Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -37.35 %
2nd Quarter June -98.46 %
1st Quarter March -72.18 %
FY (Year on Year)   -


Back to BEAM Growth rate Comparisons >> Back to BEAM Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #71
Healthcare Sector #568
Overall #3918

Revenue Y/Y Growth Statistics
High Average Low
851050 % 25693.72 % -99.99 %
(Jun 30 2022)   (Dec 31 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #71
Healthcare Sector #568
Overall #3918
Revenue Y/Y Growth Statistics
High Average Low
851050 % 25693.72 % -99.99 %
(Jun 30 2022)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Beam Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
299700 % 5741.46 % -99.99 %
(Dec 31 2019)  


BEAM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Beam Therapeutics Inc disclosed fall in Revenue from the second quarter by -37.35% to $ 0.31 millions, from $ 0.49 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Beam Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3886.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #74
Healthcare Sector #590
Overall #3886
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #74
Healthcare Sector #590
Overall #3886
Revenue Q/Q Growth Statistics
High Average Low
299700 % 5741.46 % -99.99 %
(Dec 31 2019)  


BEAM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Beam Therapeutics Inc disclosed fall in Revenue from the second quarter by -37.35% to $ 0.31 millions, from $ 0.49 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Beam Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3886.


Beam Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 146.64
Y / Y Revenue Growth (TTM) 163.27 %
Year on Year Revenue Growth Overall Ranking # 3669
Seqeuential Revenue Change (TTM) -6.02 %
Seq. Revenue Growth (TTM) Overall Ranking # 2964


Cumulative Revenue growth Comment
Although Beam Therapeutics Inc 's Annual Revenue growth year on year were below company's average 16660.3% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 163.27% year on year, from 158.88% in Jun 30 2026.

In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2194 to 3669.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 528
Overall # 3669

Revenue TTM Y/Y Growth Statistics
High Average Low
320383.33 %
 16660.3 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 413
S&P 500 # 2964
Cumulative Revenue growth Comment
Although Beam Therapeutics Inc 's Annual Revenue growth year on year were below company's average 16660.3% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 163.27% year on year, from 158.88% in Jun 30 2026.

In the Healthcare sector 527 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2194 to 3669.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 528
Overall # 3669

Revenue TTM Y/Y Growth Statistics
High Average Low
320383.33 %
16660.3 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 413
S&P 500 # 2964




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BEAM's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Beam Therapeutics Inc Revenue Growth Rates (BEAM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Beam Therapeutics Inc (CIK 1745999).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-444455
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Beam Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.